SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM
BOSTON SCIENTIFIC CORPORATION · Decision date Sep 28, 2012
What did the FDA approve?
The FDA database entry records an original PMA approval for the Subcutaneous Implantable Defibrillator (S-ICD) System, dated September 28, 2012. The approved indication is defibrillation therapy for life-threatening ventricular tachyarrhythmias in patients who do not have symptomatic bradycardia, incessant ventricular tachycardia, or spontaneous, frequently recurring ventricular tachycardia that is reliably terminated with antitachycardia pacing.
The applicant is Boston Scientific Corporation, and the device is classified under product code LWS as an implantable cardioverter defibrillator (non-CRT) in the cardiovascular specialty. The entry contains no supplement type or supplement reason, and the statement does not report clinical outcomes or comparative safety data.
FDA approval order statement
APPROVAL FOR THE SUBCUTANEOUS IMPLANTABLE DEFIBRILLATOR (S-ICD) SYSTEM. THIS DEVICE IS INDICATED TO PROVIDE DEFIBRILLATION THERAPY FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYARRHYTHMIAS INPATIENTS WHO DO NOT HAVE SYMPTOMATIC BRADYCARDIA, INCESSANT VENTRICULAR TACHYCARDIA, OR SPONTANEOUS, FREQUENTLY RECURRING VENTRICULAR TACHYCARDIA THAT IS RELIABLY TERMINATED WITH ANTITACHYCARDIA PACING.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 28, 2012
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110042
- Regulatory pathway
- Premarket approval application
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- LWS
- Decision code
- APPR
- Decision date
- Sep 28, 2012
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable cardioverter defibrillator (non-CRT).
- Applicant
- Boston Scientific Corporation
- Product code
- LWS
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P110042 received
Application receipt date recorded by FDA.
P110042 · FDA decision
APPR
P110042/S216 · Related supplement
EMBLEM Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) high voltage (HV) Capacitor
Timeline entries are records held by MedtechLedger for P110042. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110042
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 2, 2026 | FDA |
Explore the linked device profile
Other records with product code LWS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Nov 5, 2026 | FDA | |
| Medtronic Cardiac Rhythm Disease Management | PMA supplement | Nov 4, 2026 | FDA | |
Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICDP980016/S967 | Medtronic Cardiac Rhythm Disease Management | PMA supplement | Oct 29, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: P110042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


